Helmholtz-zentrum Fuer Infektionsforschung Gmbh

Verena Fetz

Mark Broenstrup

Werner Tegge

Stephan Huettel

Bushra Rais

Kevin Ferreira

Galina Sergeev

Katrin I Mohr

Philipp Klahn

Wera Collisi

Haiyu Hu

The present invention is directed to novel natural product-derived ratjadone-based compounds useful as payloads (or toxins) in drug-conjugates constructs with cell target binding moieties (CTBM) and payload-linker compounds useful in connection with drug conjugates. The present invention further relates to new ratjadone compositions including the aforementioned payloads, payload-linkers and drug conjugates, and methods for using these payloads, payload-linkers and drug conjugates, to treat pathological conditions including cancer, inflammatory and infectious diseases.

Targeted cytotoxic ratjadone derivatives and conjugates thereof

The present invention relates to new compounds comprising a siderophore moiety as well as a core structure able to chelate a metal ion. Optionally, the compounds may have additionally a moiety with a functional element including a marker molecule, a bioactive agent, an activity based probe suitable to monitor the aberrant expression or activity of proteins involved in the initiation and progression of bacterial infection, or a compound useful for bacterial inhibition. In a further aspect, the present invention provides a pharmaceutical composition containing said compound, for example, said pharmaceutical composition is an antibiotic. Additionally, the present invention relates to the use of said compounds in diagnostic methods, in particular, imaging methods including SPEC, PET or MRI. In an embodiment of the present invention, the compound is part of a theranostic composition having both, therapeutic as well as diagnostic activities.

1,4,7,10-tetrazacyclododecane based agents to target bacteria and its use

Growing community of inventors

Berlin, Germany

Verena Fetz